Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
← catalyst calendarNCT06676319 · readout in 305 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
556actual
Sites
230
Countries
Argentina, Belgium, Brazil +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-07 | actual | When the study began enrolling |
| Primary completion | 2027-06-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-19 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Interventions
- Drug: Lunsekimig — also filed as SAR443765
- Drug: Short-Acting Beta Agonists (SABA)
- Drug: Placebo
- Drug: Fluticasone/Salmeterol
- Drug: Budesonide/Formoterol
- Drug: Budesonide/Albuterol
Primary outcome
what the primary-completion date above is the date OFAnnualized rate of asthma exacerbation events
measured From baseline up to 52 weeks
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed